Amrutanjan Healt reports strong financial performance in Q1 2024, receives 'Buy' call from MarketsMOJO
Amrutanjan Healt, a smallcap pharma company, has reported a positive financial performance for the quarter ended Mar 2024. The company's PAT has increased by 32.89% year on year, while net sales have grown by 26.65%. MarketsMojo has given a 'Buy' call for the company's stock, indicating potential growth in the pharma industry.
Amrutanjan Healt, a smallcap pharma company, has recently declared its financial results for the quarter ended Mar 2024. The company has shown a positive performance with a score of 7 out of 11, an improvement from the previous quarter.
One of the key highlights of the financial results is the growth in Profit After Tax (PAT) for the half-yearly period, which has increased by 32.89% year on year. This shows a strong financial performance and a positive trend in the near term. Additionally, the company's net sales for the quarter have also shown a significant growth of 26.65% year on year, with the highest sales in the last five quarters.
The company's Profit Before Tax less Other Income (PBT) has also seen a growth of 25.75% year on year, indicating a positive trend in the near term. However, the company's Non Operating Income has shown a significant increase, which may not be sustainable in the long run.
MarketsMOJO, a leading stock analysis platform, has given a 'Buy' call for Amrutanjan Healt based on its financial performance. This is a positive sign for investors looking to invest in the company's stock.
Overall, Amrutanjan Healt has shown a strong financial performance in the quarter ended Mar 2024, with positive trends in key financial indicators. This is a promising sign for the company's growth in the pharma industry.
{{stockdata.stock.price.value}} {{stockdata.stock.price_difference.value}} ({{stockdata.stock.price_percentage.value}}%)
{{stockdata.stock.date.value}} | BSE+NSE Vol: {{stockdata.index_name}} Vol: {{stockdata.stock.bse_nse_vol.value}} ({{stockdata.stock.bse_nse_vol_per.value}}%)
Related Stock Links
- {{stockdata.stock.stock_name.value}} Analysis
- {{stockdata.stock.stock_name.value}} Technicals
- {{stockdata.stock.stock_name.value}} Quality
- {{stockdata.stock.stock_name.value}} Valuation
- {{stockdata.stock.stock_name.value}} Financial Trend
- {{stockdata.stock.stock_name.value}} Return Analysis
- {{stockdata.stock.stock_name.value}} Price Analysis
- {{stockdata.stock.stock_name.value}} Quarterly Result Analysis
- {{stockdata.stock.stock_name.value}} Half-Yearly Result Analysis
- {{stockdata.stock.stock_name.value}} Nine Monthly Result Analysis
- {{stockdata.stock.stock_name.value}} Annual Results
- {{stockdata.stock.stock_name.value}} Balance Sheet
- {{stockdata.stock.stock_name.value}} Profit & Loss
- {{stockdata.stock.stock_name.value}} Cash Flow
- {{stockdata.stock.stock_name.value}} News
- {{stockdata.stock.stock_name.value}} Announcements
- {{stockdata.stock.stock_name.value}} Share Holding
- {{stockdata.stock.stock_name.value}} Peer Comparison
Our weekly and monthly stock recommendations are here
Loading...
Industry
{{sm.old_ind_name }}
Market Cap
{{sm.mcapsizerank }}
Date of Entry
{{sm.date }}
Target Price
{{sm.target_price }}
({{sm.performance_target }}%)
Holding Duration
{{sm.target_duration }}
Last 1 Year Return
{{sm.performance_1y}}%
{{sm.comp_name}} price as on {{sm.todays_date}}
₹{{sm.price_as_on}} ({{sm.performance}}%)
Industry
{{sm.old_ind_name}}
Market Cap
{{sm.mcapsizerank}}
Date of Entry
{{sm.date}}
Entry Price
{{sm.opening_price}}
Last 1 Year Return
{{sm.performance_1y}}%
Related News
Most Read
